From the Guidelines
Zavicefta (ceftazidime/avibactam) is not explicitly mentioned to be available in a 1.25g dosage in the provided evidence. The study 1 provides recommendations for antimicrobial dosages, including ceftazidime/avibactam, but does not specify the availability of a 1.25g formulation.
Key Points to Consider
- The provided evidence 1 focuses on dosage recommendations for various antimicrobial agents, including ceftazidime/avibactam, but does not discuss the availability of specific formulations.
- The standard dosage of ceftazidime/avibactam is mentioned as 50 mg/kg/dose IV q8h for children, with a maximum dose of 2000 mg ceftazidime/dose.
- There is no explicit mention of a 1.25g formulation of Zavicefta (ceftazidime/avibactam) in the provided study 1.
Clinical Implications
- In clinical practice, it is essential to consult the latest prescribing information and manufacturer's guidelines for the availability of specific formulations and dosages of medications like Zavicefta (ceftazidime/avibactam).
- The lack of information on a 1.25g dosage in the provided evidence 1 does not necessarily imply its unavailability, but rather highlights the need for further consultation of up-to-date resources.
From the Research
Zavicefta (ceftazidime/avibactam) Dosage
- The available evidence does not directly address the availability of Zavicefta (ceftazidime/avibactam) in a 1.25g dosage.
- However, the studies provide information on the dosing regimens of ceftazidime-avibactam used in clinical trials, such as 2.5 g over 2 h every 8 h 2.
- Additionally, the studies mention the approved dose of ceftazidime-avibactam, but do not specify the exact dosage strength available 3, 2.
- It is worth noting that the calibration ranges for ceftazidime and avibactam in plasma and dried blood spots were reported in one study, but these values are not directly related to the dosage strength of Zavicefta 4.
Clinical Use of Zavicefta
- Zavicefta is approved for the treatment of adults with complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired pneumonia, and other infections caused by aerobic Gram-negative organisms in patients with limited treatment options 3.
- The clinical efficacy of ceftazidime-avibactam has been demonstrated in pivotal phase III non-inferiority trials with carbapenem comparators 3.
- Ceftazidime-avibactam has been shown to be generally well tolerated, with a safety and tolerability profile consistent with that of ceftazidime alone and that was generally typical of the injectable cephalosporins 3, 2.